PNAS: New breakthrough: Blocking a protein to suppress liver and bile duct cancer

Liver cancer is one of the most commondigestivecancerinopathic cancer in China, about 110,000 people die of liver cancer every year, accounting for 45% of the world's liver cancer deathsBile duct cancer is a malignant tumor that occurs in the bile duct system and is a more common malignant tumor diseaseThe incidence of these two diseases is high and difficult to treatSpanish scientists have discovered a protein that can inhibit the development of liver and bile duct cancerResearchers have found a mechanism to control the development of liver cancerThe study was published in the Proceedings of the National Academy of Sciences (PNAS)Partially funded by the Spanish Association against CancerThe study found a protein that, when blocked, significantly reduces the effects and progression of bile duct cancerthis work was made possible by researchers at the Computer Network Information Center (CNIC) of the Chinese Academy of Sciences, who developed an animal model where changes in bile acid production have been shown to be the cause of this type of tumorliver cancer is the fifth most common cancer in the world and the second leading cause of cancer-related deathsBile duct cancer is the second most common form of liver cancer, which begins with the development of bile ducts and clinicalanostic developmentWith no early markers, most patients are diagnosedlate stage slate and die as cancer spreads or metastasesin the case by Guadalupe Sabio, Alfonso Mora and Roger JJDavis (Roger JJIn the study led by Davis, mice with livers that did not contain JNK1 and JNK2 proteins were bred"When we eat too much, these proteins are activated and, to some extent, lead to excessive storage of fat in the liver (i.efatty liver or fatty degeneration)," DrSabio explainsAnd lead to insulin resistance, so these proteins are important for the study of obesity anddiabetesTheresearchers also found that these two proteins control the production of bile acids in the liver, which are essential for properdigestion of fatsand the absorption of fat-soluble vitamins (A, D, E and K)Lack of JNK1 and JNK2 in the liver led to changes in enzymes responsible for the metabolism ofcholesteroland bile acid, and in the mice analyzed, too much bile acid in the blood could be seen The lack of jNK in the liver alters the production of bile acid sourcitand and causes the accumulation of bile the researchers explain that over time, the accumulation of bile acid has a "toxic effect" on the liver The bile ducts begin to over-hyperplify, triggering the formation of multiple bile duct cancers, and clinical markers are very similar to those in patients with these types of cancer In fact, this is the first time they have seen an increase in markers in patients with bile duct cancer in a mouse model This suggests that these mice could provide new clues to the evaluation of new bile duct cancer treatments The lack of progress in hepatic JNK for bile duct cancer this model led CNIC researchers to researchers at the University of Massachusetts School of Medicine in the United States and Roger J J Davis' lab worked together to find a protein that plays a key role in the development of tumors, PPAR The protein regulates the metabolism of bile acid and liver fat PPAR defects can reduce liver cancer caused by jNK defects in the liver
although it is not yet known whether the data can be inferred from human patients, but in fact the presence of the first animal model will allow the study of a tumor that is still only diagnosed at a late stage, when metastasis has occurred early studies show editing that JNK blocking can prevent the development of liver fat degeneration That's why various clinical trials have been launched for these protein inhibitors The researchers believe the new findings are a wake-up call for these drugs Although the work was only tested in mice, the researchers noted that we must be careful to be vigilant about the liver outcomes of patients treated with these new drugs